// App-Quantinova.ai

PB1082 : Mode of Delivery in Haemophilia: Vaginal Delivery and Cesarean Section Carry Similar Risk for Inhibitor Development in Severe Haemophilia A

Researchers

Presenter

  • J. Tarrant

Principal Investigators

  • N. Andersson

  • E. Chalmers

  • G. Kenet

  • R. Ljung

  • A. Mkipernaa

  • H. Chambost

  • M. van den Berg

Medical Centers

  • Queens University, Kingston, Canada

  • Skåne University Hospital, Centre for Thrombosis and Hemostasis, Malmö, Sweden

  • Lund University, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden

  • Royal Hospital for Children, Department of Paediatric Gastroenterology, Glasgow, United Kingdom

  • Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, National Hemophilia Center, Tel Aviv, Israel

  • Helsinki University Hospital, University of Helsinki, Children's Hospital and Hematology, Comprehensive Cancer Center, Helsinki, Finland

  • Children Hospital La Timone, Pediatric Haematology Oncology Department, Marseille, France

  • Aix Marseille Université, INSERM, INRA, C2VN, Faculté de Médecine, Marseille, France

  • PedNet Haemophilia Research Foundation, Baarn, Netherlands

Locations

  • Canada

  • Sweden

  • United Kingdom

  • Israel

  • Finland

  • France

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved